SCHEMBL5389541

SCHEMBL5389541

Cc1c(Cl)cccc1S(=O)(=O)Nc1nnc(COc2ccc([N+](=O)[O-])cc2)s1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HPGD P15428 2/20 0.56
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.51
POLB P06746 1/20 0.51
AMY1A P0DUB6 1/20 0.47
RECQL P46063 1/20 0.42
HSD11B1 P28845 2/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5398285 0.88 NPC1 (0.54) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL5396556 0.87 MEN1 (0.47) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL5401332 0.78 MAPT (0.49) ALDH1A1HPGDKMT2AMEN1RECQL
SCHEMBL5397908 0.78 ATM (0.59) KMT2AMEN1POLBHSD11B1GAA
SCHEMBL5830908 0.77 AMY1A (0.50) ALDH1A1HPGDKMT2AMEN1AMY1A
SCHEMBL5831102 0.76 HSD11B1 (0.49) ALDH1A1HSD11B1
SCHEMBL5389548 0.75 MAPT (0.56) ALDH1A1KMT2AMEN1RECQLHSD11B1
SCHEMBL5831865 0.75 ALDH1A1 (0.47) ALDH1A1RECQLHSD11B1SMN1; SMN2
SCHEMBL5831070 0.75 HSD11B1 (0.48) ALDH1A1HSD11B1
SCHEMBL1472205 0.75 MEN1 (0.57) ALDH1A1HPGDKMT2AMEN1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US claimed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US claimed
EP-1631558-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2006-03-08 EP claimed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US claimed
WO-2004103980-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I BIOVITRUM AB (SE) 2004-12-02 WO claimed
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2007-03-22 US disclosed
US-7173030-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2007-02-06 US disclosed
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009821-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 53/4885HPGD 44/4885KMT2A 3325/4885
US-20070066614-A1 Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 ALDH1A1 36/4885HPGD 38/4885KMT2A 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.